Carregando...
Efficacy and safety of MYL‐1501D versus insulin glargine in people with type 1 diabetes mellitus: Results of the INSTRIDE 3 phase 3 switch study
AIMS: To assess the efficacy, insulin dose, safety and immunogenicity when people with type 1 diabetes mellitus switched between MYL‐1501D and reference insulin glargine (Lantus®; Sanofi‐Aventis US LLC, Bridgewater, New Jersey). MATERIALS AND METHODS: Eligible participants from INSTRIDE 1 who comple...
Na minha lista:
| Publicado no: | Diabetes Obes Metab |
|---|---|
| Principais autores: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Blackwell Publishing Ltd
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7065063/ https://ncbi.nlm.nih.gov/pubmed/31691472 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13904 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|